Chronic total coronary occlusion in patients with intermediate viability: value of low-dose dobutamine and contrast-enhanced 3-T MRI in predicting functional recovery in patients undergoing percutaneous revascularisation with drug-eluting stent

Radiol Med. 2009 Aug;114(5):692-704. doi: 10.1007/s11547-009-0426-2. Epub 2009 Jun 23.
[Article in English, Italian]

Abstract

Purpose: Myocardial viability was evaluated by magnetic resonance imaging (MRI) in patients with chronic total coronary occlusion (CTO) treated with a drug-eluting stent. Change in left ventricular ejection fraction (LVEF) was analysed.

Materials and methods: Twenty-three patients with CTO underwent delayed-enhancement (DE) and low-dose dobutamine MRI (LD). Diastolic wall thickness (DWT), dobutamine-induced systolic wall thickening (SWT) and DE transmural extension were quantitatively assessed in vessel-related segments, calculating the contribution of viable tissue to SWT, expressed as viability index (VI)=[SWTx(100 - DE)]/100. Patients with transmural enhancement were excluded from revascularisation. At 6 months follow-up, patients underwent coronary angiography (CA) and MRI. Functional recovery was defined as a 2-mm increase in SWT.

Results: Transmural enhancement (mean DE 62.88+/-37.18] was present in three patients. Mean DWT, SWT, VI and DE of recanalised patients were 8.03+/-2.35, 2.64+/-1.56, 1.77+/-1.48 mm and 41.97+/-30.32. Revascularisation was successful in 14/16. Follow-up CA showed patency of treated vessels. Functional recovery was achieved in 13 patients. Functional recovery showed significant correlation with SWT (beta 1,779, p=0.015), and even higher correlation with VI (beta 2.032, p=0.011). LVEF improved significantly [Delta 95% confidence interval (CI) -4.47, p=0.0203).

Conclusions: Invasive CTO treatment has beneficial effects on myocardial contractility that can be predicted by VI, and on LVEF.

MeSH terms

  • Aged
  • Cardiotonic Agents*
  • Chronic Disease
  • Contrast Media
  • Coronary Stenosis / physiopathology
  • Coronary Stenosis / therapy*
  • Dobutamine*
  • Drug-Eluting Stents*
  • Female
  • Heterocyclic Compounds
  • Humans
  • Linear Models
  • Magnetic Resonance Imaging / methods*
  • Male
  • Myocardial Revascularization
  • Organometallic Compounds
  • Predictive Value of Tests
  • Recovery of Function
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • Dobutamine
  • gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate